Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells

被引：91

作者：

Gaspar, Nathatie ^{[3
,4
,5
]}

Sharp, Swee Y.

Pacey, Simon

Jones, Chris ^{[3
,4
]}

Walton, Mchael

Vassal, Gilles ^{[5
]}

Eccles, Suzanne ^{[2
]}

Pearson, Andrew ^{[3
,4
]}

Workman, Paul ^{[1
]}

机构：

[1] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Haddow Labs, Signal Transduct & Mol Pharmacol Team, Sutton SM2 5NG, Surrey, England

[2] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Tumour Biol & Metastasis Team, Sutton SM2 5NG, Surrey, England

[3] Inst Canc Res, Sect Paediat Oncol, Sutton SM2 5NG, Surrey, England

[4] Royal Marsden Hosp NHS Fdn Trust, Sutton, Surrey, England

[5] Univ Paris 11, UPRES EA 3535, IFR54, Inst Cancerol Gustave Roussy, Villejuif, France

来源：

CANCER RESEARCH | 2009年 / 69卷 / 05期

关键词：

HSP90 MOLECULAR CHAPERONE; SHOCK-PROTEIN; 90; PHASE-I; HEAT-SHOCK-PROTEIN-90; INHIBITORS; BREAST-CANCER; NAD(P)H-QUINONE OXIDOREDUCTASE-1; ANSAMYCIN ANTIBIOTICS; DT-DIAPHORASE; SOLID TUMORS; LINES;

D O I：

10.1158/0008-5472.CAN-08-3131

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Heat shock protein 90 (HSP90) inhibitors, such as 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin), which is currently in phase II/phase M clinical trials, are promising new anticancer agents. Here, we explored acquired resistance to HSP90 inhibitors in glioblastoma (GB), a primary brain tumor with poor prognosis. GB cells were exposed continuously to increased 17-AAG concentrations. Four 17-AAG-resistant GB cell lines were generated. High-resistance levels with resistance indices (RI = resistant line IC50/parental line IC50) of 20 to 137 were obtained rapidly (2-8 weeks). After cessation of 17-AAG exposure, RI decreased and then stabilized. Cross-resistance was found with other ansamycin benzoquinones but not with the structurally unrelated HSP90 inhibitors, radicicol, the purine BIIB021, and the resorcinylic pyrazole/isoxazole amide compounds VER-49009, VER-50589, and NVP-AUY922. An inverse correlation between NAD(P)H/quinone oxidoreductase 1 (NQ01) expression/activity and 17-AAG IC50 was observed in the resistant lines. The NQ01 inhibitor ES936 abrogated the differential effects of 17-AAG sensitivity between the parental and resistant lines. NQ01 mRNA levels and NQ01 DNA polymorphism analysis indicated different underlying mechanisms: reduced expression and selection of the inactive NQ01*2 polymorphism. Decreased NQ01 expression was also observed in a melanoma line with acquired resistance to 17-AAG. No resistance was generated with VER-50589 and NVP-AUY922. In conclusion, low NQ01 activity is a likely mechanism of acquired resistance to 17-AAG in GB, melanoma, and, possibly, other tumor types. Such resistance can be overcome with novel HSP90 inhibitors. [Cancer Res 2009;69(5):1966-75]

引用

页码：1966 / 1975

页数：10

共 50 条

[31] Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I Dose-Escalation study [J].

Modi, Shanu ;

Stopeck, Alison T. ;

Gordon, Michael S. ;

Mendelson, David ;

Solit, David B. ;

Bagatell, Rochelle ;

Ma, Weining ;

Wheler, Jennifer ;

Rosen, Neal ;

Norton, Larry ;

Cropp, Gillian F. ;

Johnson, Robert G. ;

Hannah, Alison L. ;

Hudis, Clifford A. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (34) :5410-5417

[32] Heat shock protects HCT116 and H460 cells from TRAIL-induced apoptosis [J].

Özören, N ;

El-Deiry, W .

EXPERIMENTAL CELL RESEARCH, 2002, 281 (02) :175-181

[33] DNA methylator and mismatch repair phenotypes are not mutually exclusive in colorectal cancer cell lines [J].

Pao, MM ;

Liang, GN ;

Tsai, YC ;

Xiong, ZG ;

Laird, PW ;

Jones, PA .

ONCOGENE, 2000, 19 (07) :943-952

[34] Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth [J].

Premkumar, DR ;

Arnold, B ;

Pollack, IF .

MOLECULAR CARCINOGENESIS, 2006, 45 (05) :288-301

[35] Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-emethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers [J].

Ramanathan, RK ;

Trump, DL ;

Eiseman, JL ;

Belani, CP ;

Agarwala, SS ;

Zuhowski, EG ;

Lan, J ;

Potter, DM ;

Ivy, SP ;

Ramalingam, S ;

Brufsky, AM ;

Wong, MKK ;

Tutchko, S ;

Egorin, MJ .

CLINICAL CANCER RESEARCH, 2005, 11 (09) :3385-3391

[36] Functions and distribution of NQO1 in human bone marrow: Potential clues to benzene toxicity [J].

Ross, D .

CHEMICO-BIOLOGICAL INTERACTIONS, 2005, 153 :137-146

[37]

Russell JS, 2003, CLIN CANCER RES, V9, P3749

[38] Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues [J].

Sharp, Swee Y. ;

Prodromou, Chrisostomos ;

Boxall, Kathy ;

Powers, Marissa V. ;

Holmes, Joanna L. ;

Box, Gary ;

Matthews, Thomas P. ;

Cheung, Kwai-Ming J. ;

Kalusa, Andrew ;

Janmes, Karen ;

Hayes, Angela ;

Hardcastle, Anthea ;

Dymock, Brian ;

Brough, Paul A. ;

Barril, Xavier ;

Cansfield, Julie E. ;

Wright, Lisa ;

Surgenor, Allan ;

Foloppe, Nicolas ;

Hubbard, Roderick E. ;

Aherne, Wynne ;

Pearl, Laurence ;

Jones, Keith ;

McDonald, Edward ;

Raynaud, Florence ;

Eccles, Sue ;

Drysdale, Martin ;

Workman, Paul .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (04) :1198-1211

[39] In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors [J].

Sharp, Swee Y. ;

Boxall, Kathy ;

Rowlands, Martin ;

Prodromou, Chrisostomos ;

Roe, S. Mark ;

Maloney, Alison ;

Powers, Marissa ;

Clarke, Paul A. ;

Box, Gary ;

Sanderson, Sharon ;

Patterson, Lisa ;

Matthews, Thomas P. ;

Cheung, Kwai-Ming J. ;

Ball, Karen ;

Hayes, Angela ;

Raynaud, Florence ;

Marais, Richard ;

Pearl, Laurence ;

Eccles, Sue ;

Aherne, Wynne ;

McDonald, Edward ;

Workman, Paul .

CANCER RESEARCH, 2007, 67 (05) :2206-2216

[40] EFFECTS OF A NEW ANTIESTROGEN, IDOXIFENE, ON CISPLATIN-SENSITIVE AND DOXORUBICIN-SENSITIVE AND DOXORUBICIN-RESISTANT HUMAN OVARIAN-CARCINOMA CELL-LINES [J].

SHARP, SY ;

ROWLANDS, MG ;

JARMAN, M ;

KELLAND, LR .

BRITISH JOURNAL OF CANCER, 1994, 70 (03) :409-414

← 1 2 3 4 5 →